miR-124 — The MicroRNA Reset
Obefazimod hit in both Phase 3 UC induction trials. Formation Bio licensed a second miR-124 activator 12 days ago. A novel mechanism that resets immune balance rather than blocking a single cytokine.
1. miR-124 — The MicroRNA That Resets Immune Balance
MicroRNA-124 (miR-124) is a small non-coding RNA that acts as a natural anti-inflammatory brake in the body. miR-124 levels are reduced in patients with inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, and other chronic inflammatory conditions. When miR-124 is depleted, pro-inflammatory pathways run unchecked.
Unlike drugs that block individual cytokines (anti-TNF, anti-IL-23, anti-IL-4Rα), miR-124 operates upstream — it simultaneously downregulates multiple pro-inflammatory pathways including IL-6/STAT3, AREG, and CDK6, while promoting anti-inflammatory regulatory T-cell function. As David Rubin, MD (University of Chicago) described obefazimod’s mechanism: “Rather than targeting specific active inflammation, it shuts it off at the source, resetting a balance of the immune system.”
This makes miR-124 enhancers fundamentally different from every other drug in the IBD landscape. They don’t block one pathway — they restore the body’s natural regulatory machinery.
Obefazimod (ABX464) — First-in-Class
Obefazimod is a first-in-class oral small molecule that enhances miR-124 expression by binding the cap-binding complex (CBC/ARS2), promoting the biogenesis of miR-124 from its precursor. Originally discovered in HIV research, Abivax pivoted to IBD after observing potent anti-inflammatory effects. It is the only miR-124-directed drug to have completed Phase 3 clinical trials.
2. Obefazimod — The Phase 3 Story
Obefazimod’s clinical journey has been methodical: a positive Phase 2a (2020), a strong Phase 2b with 48-week durability (2023), and then two massive parallel Phase 3 induction trials — ABTECT-1 and ABTECT-2 — enrolling 1,275 patients across 600+ sites in 36 countries. This was one of the largest Phase 3 UC programs ever conducted.
ABTECT Phase 3 Induction Results (Jul 22, 2025)
The 50mg dose met the primary endpoint of clinical remission at Week 8 in both trials:
| Endpoint | ABTECT-1 | ABTECT-2 | Pooled |
|---|---|---|---|
| Clinical remission (pbo-adj) | 19.3% (p<0.0001) | 13.4% (p=0.0001) | 16.4% |
| Endoscopic improvement | Met (p<0.0001) | Met | Met |
| Clinical response | Met | Met | Met |
| Symptomatic remission | Met | Met | Met |
| Prior advanced therapy failure | 47.3% of patients had failed prior advanced therapy including JAK inhibitors | ||
| Safety | Adverse events comparable to placebo. No new safety signals at any dose. | ||
Patient-Reported Outcomes (Sep 2025)
37% of 50mg patients reported no bowel urgency at Week 8 vs 18.1% placebo (p<0.0001). Significant improvements in quality of life, sleep, and work productivity. For UC patients, bowel urgency resolution is among the most meaningful outcomes.
Safety — The Competitive Edge
The most important feature of obefazimod may be its safety. Across all studies — Phase 1 through Phase 3, including 96-week open-label extension — adverse events were comparable to placebo. No new safety signals at any dose or duration. The Dec 2025 DSMB review of the maintenance trial (>80% completion) confirmed no safety concerns. For a field where JAK inhibitors carry boxed warnings for cardiovascular events, malignancy, and thrombosis, a clean safety profile is a major competitive advantage.
What’s Next: Maintenance (Q2 2026)
678 patients are enrolled in the 44-week ABTECT maintenance trial. Topline results expected Q2 2026 — this is the make-or-break readout. If positive, Abivax plans NDA submission in H2 2026 with potential FDA approval in 2027.
3. Competitive Landscape — miR-124 Activators
| Drug | Company | Mechanism | Phase | Lead Indication | Key Data | Status |
|---|---|---|---|---|---|---|
| Obefazimod (ABX464) | Abivax | Oral miR-124 enhancer (binds CBC/ARS2 complex) | Phase 3 (UC), Phase 2b (CD) | UC (NDA-track), Crohn’s disease | Phase 3 induction positive. Maintenance data Q2 2026. | First-in-class. NDA planned H2 2026. |
| FHND5032 | Formation Bio / Kenmare Bio (licensed from CTFH) | Oral miR-124 activator (small molecule) | Preclinical → Phase 1 planned 2026 | Autoimmune diseases (UC studied preclinically) | Preclinical only. “Well-characterized molecule with compelling preclinical profile.” | Licensed Jan 29, 2026 for up to $500M. AI-driven development via Forge platform. |
The miR-124 space is currently a two-company landscape. Abivax is 5+ years ahead clinically with Phase 3 data in hand. Formation Bio’s FHND5032 provides competitive validation of the mechanism and may eventually expand the market if it differentiates on indication, dosing, or combination potential.
4. The IBD Competitive Landscape — Where miR-124 Fits
| Drug | Company | Mechanism | Route | Status in UC | Key Advantage | Key Limitation |
|---|---|---|---|---|---|---|
| Infliximab (Remicade) | J&J → biosimilars | Anti-TNF | IV | Approved (generic) | Long track record, cheap biosimilars | Loss of response, immunogenicity, infections |
| Adalimumab (Humira) | AbbVie → biosimilars | Anti-TNF | SC | Approved (generic) | Convenient SC, cheap biosimilars | Same anti-TNF limitations |
| Vedolizumab (Entyvio) | Takeda | α4β7 integrin | IV/SC | Approved | Gut-selective, clean safety | Slower onset, modest efficacy vs newer agents |
| Tofacitinib (Xeljanz) | Pfizer | JAK inhibitor (pan-JAK) | Oral | Approved | Oral, fast onset | Boxed warning: CV, malignancy, thrombosis |
| Upadacitinib (Rinvoq) | AbbVie | JAK1-selective inhibitor | Oral | Approved | Oral, highest remission rates in UC | Same JAK class safety concerns |
| Risankizumab (Skyrizi) | AbbVie | Anti-IL-23 (p19) | IV → SC | Approved | Strong efficacy, clean safety | Injectable |
| Guselkumab (Tremfya) | J&J | Anti-IL-23 (p19) | SC | Approved UC 2025 | Dual mechanism (IL-23 + CD64) | Injectable |
| Mirikizumab (Omvoh) | Eli Lilly | Anti-IL-23 (p19) | IV → SC | Approved | Strong maintenance data | Injectable, IV induction |
| Tulisokibart | Merck | Anti-TL1A | SC | Phase 3 | Novel mechanism (TL1A), strong Phase 2 | Injectable, still in Phase 3 |
| Duvakitug | Sanofi/Teva | Anti-TL1A | SC | Phase 3 | Novel mechanism, Phase 3 enrolling | Injectable, still in Phase 3 |
| Obefazimod | Abivax | miR-124 enhancer | Oral | Phase 3 (NDA planned H2 2026) | Novel MOA, oral, clean safety, works post-JAKi failure | Moderate remission rates vs JAKi; maintenance data pending |
Obefazimod’s competitive advantage is the combination of oral administration, novel mechanism (works in JAK-failure patients — 47.3% of ABTECT population), and an exceptionally clean safety profile. In a field where the two best oral options (tofacitinib, upadacitinib) carry boxed warnings, a safe oral therapy with efficacy in advanced-therapy-experienced patients fills a clear unmet need.
5. Formation Bio & Kenmare Bio — The AI-Pharma Entrant
Formation Bio is a $1.7B AI-native pharmaceutical company backed by Sanofi and a16z. Their model: license clinical-stage or near-clinical assets, then develop them faster using AI — the Forge platform for trial design and operations, and Muse (in partnership with OpenAI) for drug candidate selection.
On January 29, 2026, Formation licensed FHND5032 from Chia Tai Feng Hai (CTFH) for worldwide rights ex-China. They created a new subsidiary, Kenmare Bio, to house the asset. Deal terms include an undisclosed upfront payment, an equity stake to CTFH, milestones up to $500M, and royalties.
FHND5032 is an oral small molecule miR-124 activator studied preclinically in ulcerative colitis models. Formation plans to enter the clinic in 2026 across “a range of autoimmune diseases” — potentially expanding the miR-124 thesis beyond IBD.
What This Deal Validates
The Formation Bio deal validates two things: (1) the miR-124 mechanism has value beyond Abivax — a $1.7B company with sophisticated drug-picking AI chose this mechanism, and (2) Formation sees enough whitespace to develop a second-in-class, potentially in indications beyond IBD where Abivax has not yet ventured.
6. The Anti-Fibrotic Signal — A Potential Game-Changer for Crohn’s
At ECCO 2026 (February 21 — 11 days from now), Abivax is presenting an oral presentation titled “Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease.” This is accompanied by 21 additional abstracts with expanded ABTECT data.
Intestinal fibrosis is a major complication of Crohn’s disease that no current therapy adequately addresses. Fibrosis leads to strictures, bowel obstruction, and the need for surgery. Anti-TNFs, IL-23 inhibitors, and JAK inhibitors all reduce active inflammation but do not reverse established fibrosis. If obefazimod has anti-fibrotic properties on top of its anti-inflammatory activity, it would be meaningfully differentiated from every other IBD drug on the market or in development.
Important caveat: This is a preclinical finding and must be confirmed in human studies. The ENHANCE-CD Phase 2b trial in Crohn’s disease (initiated Oct 2024) may provide the first clinical signal. But if the anti-fibrotic effect translates, it opens a potentially massive additional market in stricturing Crohn’s disease — a population with no effective medical therapy today.
7. Bull/Bear Case
Bull Case
- Phase 3 induction data positive in both ABTECT-1 and ABTECT-2. NDA-track.
- Novel mechanism — works in patients who failed JAK inhibitors (47.3% of trial population)
- Oral administration with placebo-like safety profile across all studies
- Anti-fibrotic signal could differentiate in Crohn’s disease
- Maintenance DSMB review clean (>80% completion, no safety signals) — positive predictor
- Formation Bio deal validates mechanism beyond a single company
- IBD market expanding rapidly: UC market projected >$15B by 2030
Bear Case
- Abivax is severely cash-constrained (~$71M as of Jun 2025). Required fundraising to reach maintenance data. Dilution risk ongoing.
- 16.4% placebo-adjusted remission is modest vs. upadacitinib (26.1% in U-ACHIEVE-1) and risankizumab (~20% in INSPIRE)
- ABTECT-2 50mg (13.4%) was weaker than ABTECT-1 (19.3%) — inconsistency raises questions about true effect size
- Maintenance data Q2 2026 is existential — if negative, entire program collapses
- Crohn’s disease Phase 2b hasn’t read out. Crohn’s is historically harder to treat than UC.
- Competitive landscape is fierce: AbbVie (Rinvoq + Skyrizi), J&J (Tremfya), Merck (tulisokibart), Sanofi (duvakitug) all advancing
- miRNA-based therapies have a troubled history (MRX34 withdrawn). While obefazimod upregulates endogenous miR-124 (not a mimic), the association may concern investors.
Completed Catalysts
Upcoming Catalysts
Key Sources
- Abivax. “ABTECT Phase 3 Induction Results in Ulcerative Colitis.” Press release, Jul 22, 2025.
- Abivax. 2026 Corporate Outlook. Press release, Jan 2026.
- Abivax. “22 Abstracts Accepted at ECCO 2026.” Press release, Dec 17, 2025.
- Formation Bio. “Formation Bio Licenses FHND5032 miR-124 Activator.” Press release, Jan 29, 2026.
- FierceBiotech. “Abivax aces pair of phase 3 ulcerative colitis trials.” Jul 2025.
- FierceBiotech. “Formation Bio’s China shopping spree continues with miR-124 deal.” Feb 2026.
- Vermeire S et al. “Obefazimod 96-week open-label maintenance data in UC.” JCC 2025.
- BioSpace. “6 Biotechs That Could Be Big Pharma’s Next M&A Target.” Dec 2025 (Abivax profile).